Epidermal Growth Factor (EGF) is a 6-kDa polypeptide mitogen that binds to the epidermal growth factor receptor (EGFR/ErbB1) to drive proliferation, migration, differentiation, and survival of epithelial, endothelial, and mesenchymal cells. It is secreted by platelets, macrophages, keratinocytes, fibroblasts, and salivary glands, playing essential roles in wound healing, barrier maintenance, angiogenesis, and tissue remodeling. EGF signaling is dysregulated in chronic wounds, metabolic disease, and cancer.
The Construction Foreman
Think of EGF as a construction foreman arriving at a demolition site (a wound). The moment tissue is damaged, local cells send out distress signals, and EGF arrives in waves—first from platelets in the blood clot (emergency response), then from wandering macrophages (cleanup crew), and finally from the surviving keratinocytes at the wound edge (local contractors).
The foreman (EGF) carries a clipboard (the EGF molecule) and walks up to the construction office on each cell (EGFR receptor). When he taps the door twice (receptor dimerization), the office bursts into activity: phones start ringing to the corporate headquarters (nucleus), ordering new workers (cell proliferation), dispatching surveyors to map the damage (cell migration), and calling in the plumbers and electricians (differentiation into specialized cells). Meanwhile, he also radios the roads department to build new access routes (angiogenesis via endothelial cell activation).
But here's the critical part: if the foreman keeps knocking on the same doors day after day without the construction ever finishing (chronic EGF signaling), the office staff burn out and stop answering (receptor downregulation, EGFR resistance). In chronic wounds and metabolic disease, either the foreman stops showing up (reduced EGF production), or the doors are broken (impaired receptor signaling)—either way, the building never gets repaired. In cancer, the foreman goes rogue and keeps ordering new construction even when the building is already complete.
EGF binds to the extracellular domain of EGFR (ErbB1), a receptor tyrosine kinase (RTK). This binding induces receptor dimerization (either EGFR homodimerization or heterodimerization with ErbB2/HER2, ErbB3, or ErbB4) and autophosphorylation of tyrosine residues in the intracellular kinase domain:
EGF → EGFR binding → receptor dimerization → autophosphorylation of Y992, Y1045, Y1068, Y1148, Y1173
The phosphorylated tyrosines serve as docking sites for adaptor proteins, activating three major downstream pathways:
graph TD
A[EGF binds EGFR] --> B[Receptor Dimerization]
B --> C[Autophosphorylation]
C --> D[RAS-RAF-MEK-ERK pathway]
C --> E[PI3K-AKT pathway]
C --> F["PLCγ pathway"]
D --> D1[ERK1/2 activation]
D1 --> D2[c-Fos, c-Jun transcription]
D2 --> D3[Cell Proliferation]
E --> E1[AKT phosphorylation]
E1 --> E2[mTOR activation]
E2 --> E3[Cell Survival & Metabolism]
E1 --> E4[BAD phosphorylation]
E4 --> E5[Apoptosis Inhibition]
F --> F1[IP3 & DAG production]
F1 --> F2["Ca²⁺ release"]
F2 --> F3[PKC activation]
F3 --> F4[Cell Migration]
1. RAS-RAF-MEK-ERK Pathway (Proliferation)
- Phosphorylated EGFR recruits GRB2 and SOS → RAS-GTP activation
- RAS-GTP → RAF (A-RAF, B-RAF, C-RAF) activation
- RAF → MEK1/2 phosphorylation → ERK1/2 phosphorylation
- ERK1/2 translocates to nucleus → phosphorylates transcription factors (c-Fos, c-Jun, Elk-1)
- Result: expression of cyclin D1, c-Myc → G1/S phase transition → cell proliferation
2. PI3K-AKT Pathway (Survival & Metabolism)
- Phosphorylated Y1068 recruits PI3K (p85/p110 subunits)
- PI3K → PIP2 to PIP3 conversion
- PIP3 → PDK1 and AKT recruitment to membrane
- PDK1 and mTORC2 → AKT phosphorylation (Thr308, Ser473)
- AKT → mTORC1 activation (protein synthesis, autophagy inhibition)
- AKT → BAD phosphorylation → anti-apoptotic signal
- AKT → FOXO exclusion from nucleus → survival gene expression
- AKT → GSK3β inhibition → glycogen synthesis, β-catenin stabilization
3. PLCγ Pathway (Migration & Calcium Signaling)
- Phosphorylated Y992 recruits PLCγ1
- PLCγ1 → PIP2 hydrolysis → IP3 + DAG
- IP3 → Ca²⁺ release from ER → calmodulin activation → cytoskeletal remodeling
- DAG → PKC activation → integrin signaling, focal adhesion dynamics
- Result: lamellipodia formation, cell migration
Wound Healing Context:
In acute wounds, EGF is released in three waves:
- 0-24 hours: Platelet degranulation releases stored EGF into the wound bed (peak concentration 50-200 ng/mL in wound fluid)
- 24-72 hours: M2 macrophages and activated keratinocytes secrete EGF in response to IL-1β, TNF-α, and TGF-beta
- 3-7 days: Proliferating keratinocytes at the wound edge maintain autocrine/paracrine EGF signaling
Hypoxia and Oxidative Stress Regulation:
- HIF-1α (stabilized by hypoxia) upregulates EGF expression via HRE (hypoxia response elements) in the EGF promoter
- ROS (H₂O₂, superoxide) activate EGFR directly via oxidation of cysteine residues, inducing ligand-independent dimerization
- This creates a positive feedback loop in wounds: hypoxia → HIF-1α → EGF → angiogenesis → oxygen delivery
Negative Regulation:
- EGFR internalization via clathrin-coated pits (CHC22 Clathrin)
- Ubiquitination by c-Cbl → lysosomal degradation
- SOCS proteins (SOCS1, SOCS3) inhibit downstream signaling
- Protein tyrosine phosphatases (PTP1B, PTEN) dephosphorylate EGFR and AKT
Wound Healing & Barrier Integrity
EGF is the primary driver of re-epithelialization in acute wounds. In chronic wounds (diabetic ulcers, pressure ulcers, venous stasis), EGFR expression is reduced by 40-60% compared to acute wounds, and receptor responsiveness is blunted by chronic inflammation (IL-1, TNF-α) and hyperglycemia (AGEs glycate EGFR, impairing kinase activity). This represents a failure of the repair metamodel—the body cannot shift from inflammatory to proliferative phase.
Interventions:
- Topical recombinant EGF (e.g., Heberprot-P for diabetic foot ulcers) shows 60-80% healing rates at 0.075-0.150 mg doses
- Reduce chronic inflammation with SPMs (resolvins, maresins) to restore EGFR sensitivity
- Collagen scaffolds with embedded EGF prolong local bioavailability
- Address Insulin resistance—insulin and IGF-1 crosstalk with EGFR signaling via hybrid receptors
Metabolic Disease
Chronic EGFR activation (via autocrine loops in adipose tissue) contributes to insulin resistance through:
- mTORC1 overactivation → IRS-1 serine phosphorylation (blocks insulin signaling)
- ERK1/2 → inflammation via NF-κB
- Cross-talk with IGF-1R → desensitization of both pathways
In obesity, adipocyte-derived EGF drives macrophage recruitment (CCL2, MCP-1) and M1 polarization, creating a pro-inflammatory adipose niche. This is the metabolic metamodel in action: selfish immune system prioritizing inflammation over metabolic health.
Oral & Gut Barrier
Salivary EGF (0.5-5 μg/L) maintains oral mucosa and esophageal integrity. Low salivary EGF correlates with:
Interventions:
- Stimulate salivary flow (mastication, bitter herbs, Ginger)
- Colostrum supplementation (rich in EGF, 200-400 μg/L)
- Address chronic stress—cortisol suppresses salivary EGF secretion
Cancer
EGFR is overexpressed or mutated in 30% of cancers (lung, colorectal, head & neck). Constitutive activation drives uncontrolled proliferation, invasion, and angiogenesis. EGFR inhibitors (erlotinib, cetuximab) are frontline therapies. From a cPNI perspective, chronic inflammation (IL-6, TNF-α) and metabolic dysfunction (Hyperinsulinaemia) create a microenvironment that favors EGFR-driven oncogenesis—this is the inflammation-cancer axis of the disease metamodel.
Evolutionary Mismatch
EGF evolved for acute injury response in a low-inflammation baseline. Modern humans live in chronic low-grade inflammation (metaflammation), which desensitizes EGFR while maintaining elevated EGF levels—a recipe for receptor resistance (analogous to Insulin resistance). This mismatch impairs wound healing and predisposes to chronic disease.
- EGF is a 53-amino-acid polypeptide with three intramolecular disulfide bonds (MW 6,045 Da)
- Peak EGF concentration in acute wound fluid: 50-200 ng/mL at 24-48 hours post-injury
- Optimal keratinocyte migration concentration: 10-100 ng/mL in vitro
- Salivary EGF concentration: 0.5-5 μg/L (varies with circadian rhythm, stress, age)
- Colostrum EGF: 200-400 μg/L (10-fold higher than mature milk)
- EGFR expression in chronic wounds is reduced by 40-60% vs. acute wounds
- EGFR half-life after internalization: 30-60 minutes (rapid turnover)
- Hypoxia (O₂ <5%) increases EGF gene expression 2-4 fold via HIF-1α
- Diabetes reduces EGFR tyrosine kinase activity by 30-50% (due to AGEs glycation)
- EGF stimulates VEGF secretion from keratinocytes (paracrine angiogenesis signal)
- Chronic EGF signaling (>72 hours continuous) induces receptor downregulation via ubiquitin-proteasome pathway
- EGF promotes Collagen I and Collagen III synthesis in fibroblasts via TGF-β1 upregulation
- Saliva EGF levels drop 30-50% under chronic stress (cortisol inhibits salivary gland EGF production)
- Wound healing — EGF is the primary mitogen driving keratinocyte proliferation and re-epithelialization in the proliferative phase
- EGFR — The receptor tyrosine kinase that transduces EGF signals; mutated/overexpressed in many cancers
- Angiogenesis — EGF stimulates endothelial cell proliferation and upregulates VEGF secretion from epithelial cells
- HIF-1α — Hypoxia-stabilized transcription factor that upregulates EGF gene expression via hypoxia response elements
- VEGF — Synergizes with EGF to promote neovascularization; both are co-secreted by activated keratinocytes
- TGF-beta — EGF signaling upregulates TGF-β1, which then amplifies Collagen synthesis and Fibrosis
- Insulin resistance — Chronic EGFR activation via mTORC1 phosphorylates IRS-1 on serine residues, blocking insulin signaling
- Collagen — EGF promotes collagen synthesis in fibroblasts; collagen scaffolds enhance EGF bioavailability in wounds
- Platelets — First-wave EGF source in acute wounds; degranulation releases 1-5 ng EGF per 10⁶ platelets
- Macrophages — M2 macrophages secrete EGF during wound healing; M1 macrophages secrete inhibitory cytokines (TNF-α)
- Chronic inflammation — Persistent IL-1β and TNF-α downregulate EGFR expression and impair EGF signaling in chronic wounds
- diabetes — Hyperglycemia and AGEs glycate EGFR, reducing tyrosine kinase activity and EGF responsiveness
- Barrier integrity — EGF maintains epithelial tight junctions (ZO-1, occludin) in gut, oral mucosa, and skin
- Leaky gut — Reduced salivary and duodenal EGF correlates with increased intestinal permeability
- mTORC1 — EGF → PI3K → AKT → mTORC1 drives protein synthesis and cell growth; chronic activation causes metabolic dysfunction
- AKT pathway — EGF is a major activator of AKT, promoting survival, glucose uptake, and glycogen synthesis
- ROS — Hydrogen peroxide oxidizes EGFR cysteine residues, enabling ligand-independent receptor activation
- Fibroblasts — EGF stimulates fibroblast migration and collagen synthesis; dysregulation contributes to Fibrosis
- Cancer — EGFR mutations (e.g., EGFRvIII, L858R) drive oncogenesis; therapeutic target in lung, colorectal, head/neck cancers
- Cortisol — Chronic glucocorticoid exposure suppresses salivary gland EGF production, impairing oral and gut barrier repair
- Curcumin — Inhibits EGFR phosphorylation and downstream ERK/AKT signaling; may reduce pathological EGFR hyperactivation
- IL-6 — Chronic IL-6 induces SOCS3, which inhibits EGFR signaling via JAK-STAT crosstalk
- Hypoxia — Stabilizes HIF-1α, which binds hypoxia response elements in the EGF promoter to increase transcription
- Keratinocytes — Both EGF target cells and EGF-secreting cells; autocrine/paracrine loop at wound edges drives migration
- Tight junctions — EGF upregulates tight junction proteins (ZO-1, occludin, claudin-1) to restore barrier function
- Module 4 — Growth factors and wound healing
- Module 5 — Connective tissue repair, angiogenesis, and epithelial regeneration